Phytomedicine company MGC Pharmaceuticals has received approval for a dose finding study of its CimetraA formula for COVID-19.
European-based MGC Pharma, a bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines, has received approval from the Israeli Ministry of Health for a dosing study for its proprietary treatment for the effects of COVID-19, CimetrA – a nanoparticle micellar formulation consisting of curcumin and boswellia.
The study, which will recruit 240 patients into the Study in sites located in Israel, South Africa, the USA, and Russia, will determine the most effective dosage of the treatment, incorporate a full safety and pharmacovigilance profile, and an extensive pharmacokinetic profile to outline the registration and administrative process of approval for sale and use.
Additionally, it will further examine the anti-inflammatory and immune-modulatory effects the medicine through cytokine level monitoring.
Patients will continue to be observed for a 28 day follow up period in order to ensure that data is not impacted by the effects of either long or post-COVID and results will be submitted to the health authorities of Israel, the USA, South Africa, and Russia.
Co-founder and managing director of MGC Pharma, Roby Zomer, commented: “This latest dosage study is the latest step as we move closer to being in a position to apply for marketing authorisation for CimetrA in territories across the globe.
“We believe that CimetrA will prove to be a vitally important drug in the treatment of COVID-19 going forward, and look forward to sharing the results of the study in due course, along with further steps towards providing COVID-19 patients and Governments across the world a cost effective treatment to fast track patient recovery and minimise the massive cost burden of long term hospitalisation.”
The results of the study will enable MGC Pharma to determine the most effective dosage of CimetrA for treating the symptoms of COVID-19 including cytokine storms and the results will be used to provide additional evidence to regulatory authorities around the world about CimetrA’s efficacy.